TBC
NVO

Ted Buchan & Co’s Novo Nordisk NVO Stock Holding History

Ted Buchan & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.6M Buy
70,833
+32,294
+84% +$1.53M 0.95% 27
2025
Q4 		$1.96M Buy
38,539
+11,036
+40% +$564K 0.72% 32
2025
Q3 		$1.53M Buy
+27,503
New +$1.61M 0.6% 38

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Ted Buchan & Co's NVO Position: Q1 2026 in Review

Ted Buchan & Co increased its Novo Nordisk (NVO) stake by 84% in Q1 2026, buying an estimated $1.53M and bringing the position to 70,833 shares worth $2.6M. The position accounts for 0.95% of the portfolio, ranked #27.

Ted Buchan & Co first reported a position in NVO in Q3 2025 and has held it in 3 quarters since. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Ted Buchan & Co held 70,833 shares of Novo Nordisk worth $2.6M as of Q1 2026.
  • Ted Buchan & Co bought 32,294 Novo Nordisk shares in Q1 2026, an estimated $1.53M.
  • Novo Nordisk made up 0.95% of Ted Buchan & Co's portfolio in Q1 2026, its #27 holding.
  • Ted Buchan & Co first reported a position in Novo Nordisk in Q3 2025 and has held it in 3 quarters since.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Ted Buchan & Co's 13F filing for Q1 2026, filed 14 May 2026.